Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
Shirin Khambata-Ford, Christopher R. Garrett, Neal J. Meropol, Mark Basik, Christopher T. Harbison, Shujian Wu, Tai W. Wong, Xin Huang, Chris H. Takimoto, Andrew K. Godwin, Benjamin R. Tan, Smitha S. Krishnamurthi, Howard A. Burris, Elizabeth A. Poplin, Manuel Hidalgo, Jose Baselga, Edwin A. Clark, David J. Mauro
Dive into the research topics of 'Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab'. Together they form a unique fingerprint.